Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating Biomarkers World Congress 2017

Steve Soper's Biography



Steve Soper, Foundation Distinguished Professor, Director, Center of BioModular Multi-scale System for Precision Medicine, The University of Kansas

Prof. Steven A. Soper received his Ph.D. from the University of Kansas in 1989 followed by a Postdoctoral Fellowship at Los Alamos National Laboratory, where he worked on single-molecule detection for high speed sequencing of the human genome. In 1991, he joined the faculty at Louisiana State University (LSU) within the Department of Chemistry, where he filled the William H. Pryor Distinguished Chair of Chemistry. Prof. Soper also had a joint appointment in the Mechanical Engineering Department and Department of Biological Sciences. While at LSU, he founded the Center for BioModular Multi-Scale Systems, which has as its primary charge to develop enabling and transformative tools for making environmental and health-related measurements at unprecedented speeds with full process automation directly in the field. Some of these tools include monitoring air and food/water supplies for biopathogens, determining bacterial/viral infections of unknown strains in patients, evaluating brain damage/injury, sampling blood for rare cells, such as tumor cells, and their molecular analysis and sequencing genomes in near real time. These tools consist of microfluidic and nanofluidic devices make in polymers via micro- or nanoreplication.

Prof. Soper is currently Foundation Distinguished Professor, Director, Center of BioModular Multi-scale System for Precision Medicine at the University of Kansas. Prof. Soper also holds a joint appointment at Ulsan National Institute of Science and Technology in Ulsan, South Korea, where he is a World Class University Professor. Prof. Soper is currently the Editor of the Americas for the Analyst and on the Editorial Board for Journal of Fluorescence and Journal of Micro- and Nanosystems. Prof. Soper is currently serving as a permanent Member of the Nano study panel with the National Institutes of Health. As a result of his efforts, Prof. Soper has secured extramural funding totaling $45M and has published over 295 manuscripts (h index = 44) and is the author of ten patents. He is also the founder of a startup company, BioFluidica, which is marketing devices for the isolation and enumeration of rare cells. His list of awards includes Chemical Instrumentation by the American Chemical Society, the Benedetti-Pichler Award, Fellow of the AAAS, Fellow of Applied Spectroscopy, Fellow of the Royal Society of Chemistry, R&D 100 Award, Distinguished Masters Award at LSU and Outstanding Scientist/Engineer of Louisiana in 2001. Finally, Prof. Soper has granted 40 PhDs and 5 MS students under his direction.

Steve Soper Image

New Tools for Liquid Biopsies: Microfluidic Platforms for the Efficient Isolation and Molecular Profiling of Circulating Tumor Cells (CTCs), Cell Free DNA (cfDNA) and Nanovesicles (Exosomes)

Monday, 20 March 2017 at 11:15

Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com

Liquid biopsies are generating great interest within the biomedical community due to the simplicity for securing important biomarkers to manage complex diseases, such as many of the cancer-related diseases. These circulating markers consist of CTCs, cfDNA and exosomes. We are developing a suite of microfluidic devices that are can process whole blood directly and engineered to efficiently search for a variety of disease-associated liquid biopsy markers from divergent subpopulations comprising the tumor microenvironment that can supply complementary clinical information. Each microfluidic device can isolate the target with recovery >90% and sufficient purity (>80%) to enable downstream molecular analysis of the particular biomarker. The microfluidic devices are made from thermoplastics via injection molding to allow for mass-production of devices with tight compliancy to accommodate clinical implementation. In this presentation, information will be shared on the operational parameters of these devices for the selection of liquid biopsy markers, and the downstream molecular information that can be garnered from the isolated markers in diseases such as colorectal, ovarian, breast, pancreatic and prostate cancers as well as some of the liquid-based cancers (acute myeloid leukemia).

New Tools for Liquid Biopsies: Microfluidic Platforms for the Efficient Isolation and Molecular Profiling of Circulating Tumor Cells (CTCs), Cell Free DNA (cfDNA) and Nanovesicles (Exosomes)

Monday, 20 March 2017 at 11:15

Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com

Liquid biopsies are generating great interest within the biomedical community due to the simplicity for securing important biomarkers to manage complex diseases, such as many of the cancer-related diseases. These circulating markers consist of CTCs, cfDNA and exosomes. We are developing a suite of microfluidic devices that are can process whole blood directly and engineered to efficiently search for a variety of disease-associated liquid biopsy markers from divergent subpopulations comprising the tumor microenvironment that can supply complementary clinical information. Each microfluidic device can isolate the target with recovery >90% and sufficient purity (>80%) to enable downstream molecular analysis of the particular biomarker. The microfluidic devices are made from thermoplastics via injection molding to allow for mass-production of devices with tight compliancy to accommodate clinical implementation. In this presentation, information will be shared on the operational parameters of these devices for the selection of liquid biopsy markers, and the downstream molecular information that can be garnered from the isolated markers in diseases such as colorectal, ovarian, breast, pancreatic and prostate cancers as well as some of the liquid-based cancers (acute myeloid leukemia).


Add to Calendar ▼2017-03-20 00:00:002017-03-21 00:00:00Europe/LondonCirculating Biomarkers World Congress 2017Circulating Biomarkers World Congress 2017 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com